Business Context and Reporting Period
This Form 8-K Current Report was filed by Crinetics Pharmaceuticals, Inc. on January 7, 2026, covering events occurring on January 5 and January 6, 2026. The filing details the execution of an underwriting agreement for a public offering of common stock.
Key Financial Metrics and Transaction Details
The filing discloses a primary equity offering with the following specific metrics:
- Shares Issued: 7,620,000 shares of Common Stock.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 1,143,000 additional shares.
- Public Offering Price: $45.95 per share.
- Price to Company: $43.42275 per share.
- Expected Net Proceeds: Approximately $330.2 million (base offering) or approximately $379.8 million (if the option is fully exercised), after deducting underwriting discounts, commissions, and estimated offering expenses.
- Underwriters: Leerink Partners LLC and J.P. Morgan Securities LLC.
Note: This filing does not provide historical revenue, profit, cash flow, margin, or debt figures. Those metrics are referenced as being available in the Company's Form 10-K for the year ended December 31, 2024, and Form 10-Q for the quarter ended September 30, 2025.
Material Changes
The primary material change is the significant increase in the Company's cash liquidity resulting from the equity offering. The transaction represents a dilution of existing shareholders through the issuance of new shares. The filing does not report changes to operating results or debt levels, as it is a current report focused solely on the capital raise event.
Outlook, Risks, and Unusual Items
Closing Conditions: The offering is expected to close on January 8, 2026, subject to customary closing conditions.
Forward-Looking Statements: The report contains forward-looking statements regarding the offering and the Company's future. Management cautions that actual results may differ materially from projections due to known and unknown risks.
Risk Factors: Investors are directed to the "Risk Factors" section in the Company's periodic filings (Form 10-K and 10-Q) for a detailed discussion of risks facing Crinetics Pharmaceuticals, Inc.
Investor Verification Checklist
- Verify the final closing date of the offering (expected January 8, 2026) and whether the over-allotment option was exercised.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) for specific indemnification obligations and termination provisions.
- Consult the most recent Form 10-K and 10-Q to assess the Company's current cash runway and burn rate relative to the new proceeds.
- Confirm the exact number of shares outstanding post-offering to calculate the precise dilution impact.